Table 1. Patient characteristics.
| Characteristic | N = 45 |
|---|---|
| Median age (range) (years) | 65 (40–81) |
| Sex (male/female) | 31/14 |
| ECOG PS (0/1/2) | 16/23/6 |
| HER2 status (+/–/unknown) | 10/33/2 |
| Tumor status (unresectable/recurrence) | 27/18 |
| Site of primary tumor (U/M/L) | 18/32/30 |
| Metastatic sites (1/2/≥ 3) | 19/19/7 |
| Liver metastasis (+/–) | 10/35 |
| Peritoneal metastasis (+/–) | 26/19 |
| Ascites (no/low/medium/massive) | 20/12/5/8 |
| Number of previous therapies (2/≥ 3) | 21/24 |
| NLR (< 5/≥ 5) | 41/4 |
| GPS (0/1/2) | 25/18/2 |
ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, Human Epidermal Growth Factor Receptor 2; U/M/L, upper (U), middle (M), and lower (L) sections of the stomach; low ascites, localized buildup of ascites in the perihepatic or pelvic space; medium ascites, ascites of intermediate size; massive ascites, accumulation of ascites extending throughout the abdominal cavity; NLR, neutrophil-to-lymphocyte ratio; GPS, Glasgow prognostic score.